Egetis Therapeutics AB

Egetis Therapeutics AB is a Sweden-based pharmaceutical company specializing in the development of innovative drugs for serious rare diseases with unmet medical needs in the orphan drug segment. Formerly known as PledPharma AB, it rebranded in December 2020 and focuses on late-stage projects addressing niche therapeutic areas. Its pipeline features Emcitate, designed to treat monocarboxylate transporter 8 (MCT8) deficiency, a rare and debilitating genetic disorder lacking approved therapies. Another key candidate, Aladote, aims to mitigate acute liver injury risks from acetaminophen overdose and is advancing through phase IIb/III trials. Previously, PledOx targeted chemotherapy-induced nerve damage. Headquartered in Stockholm and founded in 2006, Egetis Therapeutics AB employs around 40 professionals dedicated to integrated drug development. Operating in the biotechnology sector, it plays a vital role in advancing treatments for orphan indications, contributing to the global effort against underserved rare conditions through rigorous clinical progression.